CBP将英国专利药品的232条款关税降至零
CBP 英文原标题： GUIDANCE: Reduction of Tariffs on Patented Pharmaceuticals and Pharmaceutical Ingredients for Products of the United Kingdom Implemented by Presidential Proclamation 11020
CBP 宣布了什么？
CBP宣布，来自英国、按HTSUS 9903.04.63申报的专利药品及相关成分，其附加关税由10%降至0%。此变更适用于2026年7月31日美东时间凌晨12:01（含）之后报关进口消费或从仓库提取消费的货物。CBP表示已更新ACE系统以反映新税率，并提示申报人参阅先前讯息中相关的第99章分类。
Allied 的立场是什么？
当时，这意味着Allied在2026年7月31日（含）之后为按9903.04.63申报的英国专利药品所办理的报关，不再适用10%的附加232条款关税，而是0%。根据我们追踪的信息，目前没有显示此税率之后有变动，但属于此类别的客户如有相关报关案件，应要求我们确认所适用的正确税率。客户不需自行采取行动；如对特定报关案件有疑问，请与我们联系。
一般信息，不构成法律意见。
CBP 消息的英文原文说了什么？
This message provides guidance regarding the reduction of tariffs on patented pharmaceuticals and associated pharmaceutical ingredients that are products of the United Kingdom amending Presidential Proclamation 11020, “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States.”
BACKGROUND
On July 31, 2026, the Secretary of Commerce published “Notice of Reduction of Tariffs on Patented Pharmaceuticals and Pharmaceutical Ingredients for Products of the United Kingdom Implemented by Presidential Proclamation 11020 (https://www.federalregister.gov/public-inspection/2026-15799/reduction-of-tariffs-patented-pharmaceuticals-and-pharmaceutical-ingredients-for-products-of-the)” reducing the tariff rate for patented pharmaceuticals and associated pharmaceutical ingredients that are products of the United Kingdom from 10 percent to 0 percent, effective July 31, 2026.
CBP has completed the necessary updates in the Automated Commercial Environment (ACE).
GUIDANCE
This guidance instructs importers, brokers, and filers on submitting entries to U.S. Customs and Border Protection (CBP) on patented pharmaceuticals and associated ingredients imported from the United Kingdom under Harmonized Tariff Schedule of the United States (HTSUS) heading 9903.04.63.
Effective with respect to goods entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 a.m. Eastern Time on July 31, 2026:
9903.04.63: Applies to patented pharmaceutical articles that are the product of the United Kingdom, as defined in U.S. note 40(c) and (g) to subchapter III.
0% additional ad valorem duty rate.
Refer to CSMS # 69395344 (https://content.govdelivery.com/bulletins/gd/USDHSCBP-422e390?wgt_ref=USDHSCBP_WIDGET_2) for Chapter 1–97 HTSUS classifications which correspond to heading 9903.04.63, and the other Chapter 99 headings established by Proclamation 11020.
For questions regarding Section 232 entry filing, contact the Trade Remedy Branch at TradeRemedy@cbp.dhs.gov (mailto:TradeRemedy@cbp.dhs.gov).
If you encounter any errors in filing an entry summary, contact your CBP client representative or the ACE Help Desk.
此消息使用了哪些术语？
每周通过电子邮件接收 CBP 消息
每周一封英文电子邮件，列出新的 CSMS 消息，并附通俗摘要和我们的立场。您可以随时取消订阅。